Isocorydine (Synonyms: NSC 32979) |
Catalog No.GC38414 |
La isocoridina se aÍsla de Dicranostigma leptopodum (Maxim.) Fedde (DLF). La combinaciÓn de isocoridina con doxorrubicina (DOX) tiene un potencial prometedor para erradicar el carcinoma hepatocelular (CHC).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 475-67-2
Sample solution is provided at 25 µL, 10mM.
Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC)[1].
Isocorydine (0-400 ug/ml; 48 hours) show a significant decrease in the IC50 for ICD and DOX, the CI values are 0.605, 0.644, 0.804, and 0.707 respectively for Huh-7, Hep-G2, SNU-449 and SNU-387[1]. Isocorydine (0-400 ug/ml; 48 hours) abrogates DOX-induced upregulation of mesenchymal markers and the downregulation of epithelial markers in human HCC cell lines[1]. Cell Viability Assay[1] Cell Line: Huh-7, Hep-G2 , SNU-387, SNU-449 cells
Isocorydine (intraperitoneal injection; 0.4 mg/kg; every 2 days for 2 weeks) retards the tumor growth, but the combined treatment of Doxorubicin (DOX) or ICD significantly inhibits tumor growth[1]. Animal Model: Female nude mice[1]
[1]. Pan JX, et al. Isocorydine suppresses doxorubicin-induced epithelial-mesenchymal transition via inhibition of ERK signaling pathways in hepatocellular carcinoma. Am J Cancer Res. 2018 Jan 1;8(1):154-164. eCollection 2018.
Average Rating: 5
(Based on Reviews and 14 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *